安罗替尼治疗KRAS突变型晚期肺腺癌1例

A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib

近年来,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者逐渐增多,治疗方法也明显增多,然而,目前对于靶向治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)耐药或化疗失败的三线及以上患者,国内外并没有标准的治疗方案,临床治疗效果也不尽如人意,安罗替尼是一种新型小分子多靶点酪氨酸激酶抑制剂,可强效抑制血管内皮细胞生长因子受体(vascular endothelial growth factor receptor,VEGFR)、血小板衍生生长因子受体(platelet-derived growth factor receptor,PDGFR)、纤维母细胞生长因子受体(fibroblast growth factor receptor,FGFR)和c-Kit等多个靶点,ALTER0303是一项关于安罗替尼作为晚期NSCLC三线治疗方案的临床研究,结果显示安罗替尼能显著延长晚期NSCLC患者的总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS),本文报道安罗替尼治疗KRAS突变型晚期肺腺癌1例。

In recent years, the number of advanced non-small cell lung cancer（NSCLC） patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor（EGFR）/anaplastic lymphoma kinase（ALK） or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor（VEGFR）, fibroblast growth factor receptor（FGFR）, platelet-derived growth factor receptor（PDGFR） and c-Kit. ALTER0303 trail, phase Ⅲ study has demonstrated that Anlotinib significantly prolonged overall survival（OS） and progression-free survival（PFS） in advanced NSCLC patients as 3 rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.